INSMED INC. overview

Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference PR Newswire BRIDGEWATER, N.J., March 25, 2025 — New Analyses from the Phase 3 ASPEN Study Examining Efficacy and Safety of Brensocatib Across a Variety of Prespecified Subgroups — — Data from ASPEN Post-hoc Analysis Evaluating Changes in Lung Function in Bronchiectasis Patients Who Did or Did Not Experience Pulmonary Exacerbations in the Trial — — Data on...

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire BRIDGEWATER, N.J., March 10, 2025 BRIDGEWATER, N.J. , March 10, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 18 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards...

Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis PR Newswire BRIDGEWATER, N.J., Feb. 24, 2025 —FDA Reaffirms Application is Under Priority Review with a PDUFA Target Action Date of August 12 , 2025— BRIDGEWATER, N.J. , Feb. 24, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class...

Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update PR Newswire BRIDGEWATER, N.J., Feb. 20, 2025 —ARIKAYCE ® (amikacin liposome inhalation suspension) Total Revenue of $104.4 Million for Fourth-Quarter and $363.7 Million for Full-Year 2024, Reflecting 19% Annual Growth and Exceeding the Upper End of Full-Year 2024 Guidance Range— —Company Reiterates 2025 Global ARIKAYCE Revenue Guidance of $405 Million to $425 Million , Reflecting Double-Digit...

Insmed To Present at March 2025 Investor Conferences PR Newswire BRIDGEWATER, N.J., Feb. 11, 2025 BRIDGEWATER, N.J. , Feb. 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: 45 th Annual TD Cowen Healthcare Conference in Boston , on Monday,...

Insmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025 PR Newswire BRIDGEWATER, N.J., Feb. 10, 2025 BRIDGEWATER, N.J. , Feb. 10, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its fourth-quarter and full-year 2024 financial results...

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire BRIDGEWATER, N.J., Feb. 7, 2025 BRIDGEWATER, N.J. , Feb. 7, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 66 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were...

FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025 PR Newswire BRIDGEWATER, N.J., Feb. 6, 2025 —Brensocatib Would be the First and Only Available Treatment for Bronchiectasis and First DPP1 Inhibitor, if Approved— BRIDGEWATER, N.J. , Feb. 6, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...